

Erminia Massarelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1340414/publications.pdf>

Version: 2024-02-01

46
papers

999
citations

759233

12
h-index

526287

27
g-index

46
all docs

46
docs citations

46
times ranked

1698
citing authors

#	ARTICLE	IF	CITATIONS
1	Postoperative Radiation Therapy Should Be Used for Completely Resected Stage III-N2 NSCLC in Select Patients. <i>Journal of Thoracic Oncology</i> , 2022, 17, 194-196.	1.1	8
2	ISA101 and nivolumab for HPV-16⁺ cancer: updated clinical efficacy and immune correlates of response. , 2022, 10, e004232.		38
3	Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 1429.	2.4	12
4	Dynamic Phenotypic Switching and Group Behavior Help Non-Small Cell Lung Cancer Cells Evade Chemotherapy. <i>Biomolecules</i> , 2022, 12, 8.	4.0	13
5	Prolonged response to checkpoint inhibitor therapy in two metastatic mucoepidermoid salivary gland carcinoma cases: a research report.. <i>Cold Spring Harbor Molecular Case Studies</i> , 2022, 8, .	1.0	3
6	LIBRETTO-001 cohort 7: A single-arm, phase 2 study of neoadjuvant selpercatinib in patients with resectable stage IB-IIIa <i>RET</i> fusion-positive NSCLC.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS8594-TPS8594.	1.6	2
7	Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e257-e265.	2.9	8
8	The Effects of Time to Treatment Initiation for Patients With Non-“small-cell Lung Cancer in the United States. <i>Clinical Lung Cancer</i> , 2021, 22, e84-e97.	2.6	19
9	Myeloid cell-“targeted STAT3 inhibition sensitizes head and neck cancers to radiotherapy and T cell-“mediated immunity. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	41
10	Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations. <i>Future Science OA</i> , 2021, 7, FSO662.	1.9	1
11	Disparate outcomes in nonsmall cell lung cancer by immigration status. <i>Cancer Medicine</i> , 2021, 10, 2660-2667.	2.8	3
12	Factors predictive of 90-day mortality after surgical resection for oral cavity cancer: Development of a recursive partitioning analysis for risk stratification. <i>Head and Neck</i> , 2021, 43, 2731-2739.	2.0	1
13	Narrative review of immunotherapy and radiation therapy in elderly patients. <i>Translational Cancer Research</i> , 2021, 10, 2620-2631.	1.0	1
14	First-time in-human study of VMD-928, an oral allosteric TrkA selective inhibitor targeting TrkA protein overexpression, in patients with solid tumors or lymphoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3081-3081.	1.6	6
15	Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 2653.	3.7	2
16	Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients. <i>Cancers</i> , 2021, 13, 2776.	3.7	9
17	The Association between Polluted Neighborhoods and <i>TP53</i> -Mutated Non-“Small Cell Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1498-1505.	2.5	8
18	Immunotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: Clinical Challenges and Future Directions. <i>Cancers</i> , 2021, 13, 3407.	3.7	4

#	ARTICLE	IF	CITATIONS
19	Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases. <i>Oncologist</i> , 2021, 26, 1052-1061.	3.7	50
20	Factors predicting for patient refusal of head and neck cancer therapy. <i>Head and Neck</i> , 2020, 42, 33-42.	2.0	17
21	An Analysis and Comparison of Survival and Functional Outcomes in Oropharyngeal Squamous Cell Carcinoma Patients Treated with Concurrent Chemoradiation Therapy within City of Hope Cancer Center Sites. <i>Journal of Clinical Medicine</i> , 2020, 9, 3083.	2.4	1
22	A Non-genetic Mechanism Involving the Integrin $\alpha 4$ /Paxillin Axis Contributes to Chemoresistance in Lung Cancer. <i>IScience</i> , 2020, 23, 101496.	4.1	27
23	Nasopharyngeal Cancer: Is the Addition of Chemotherapy to Radiotherapy Worthwhile in an Era of Value-Based Care?. <i>JCO Oncology Practice</i> , 2020, 16, 711-712.	2.9	0
24	Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure. <i>Cancers</i> , 2020, 12, 3851.	3.7	27
25	Biomarkers in immunotherapy: literature review and future directions. <i>Journal of Thoracic Disease</i> , 2020, 12, 5119-5127.	1.4	7
26	Role of immunotherapy and co-mutations on KRAS-mutant non- small cell lung cancer survival. <i>Journal of Thoracic Disease</i> , 2020, 12, 5086-5095.	1.4	29
27	Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. <i>Lung Cancer</i> , 2020, 146, 174-181.	2.0	8
28	FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 399-409.	4.1	59
29	Precision medicine and actionable alterations in lung cancer: A single institution experience. <i>PLoS ONE</i> , 2020, 15, e0228188.	2.5	7
30	INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5-FU chemotherapy (5-FU/plat), with or without pembrolizumab (PE), for the treatment of advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6544-6544.	1.6	8
31	KITE-439: A phase I study of HPV16 E7 T cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS3149-TPS3149.	1.6	1
32	Alterations in STK11 to limit response to immune checkpoint inhibitors in lung cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21503-e21503.	1.6	0
33	Evaluation of immune-related adverse events in patients treated with sequential immunotherapy and tyrosine kinase inhibitor treatment in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21562-e21562.	1.6	0
34	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
35	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
36	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0

#	ARTICLE	IF	CITATIONS
37	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
38	Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio. Lung Cancer, 2019, 133, 136-143.	2.0	21
39	Early mortality of stage IV non-small cell lung cancer in the United States. Acta OncolÃ³gica, 2019, 58, 1095-1101.	1.8	8
40	Postoperative radiation performed at the same surgical facility associated with improved overall survival in oral cavity squamous cell carcinoma. Head and Neck, 2019, 41, 2299-2308.	2.0	9
41	Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer. JAMA Oncology, 2019, 5, 67.	7.1	344
42	Perspectives in Head and Neck Medical Oncology. Cancer Treatment and Research, 2018, 174, 163-185.	0.5	5
43	Comparing outcomes of concurrent chemotherapy regimens in patients 65 years old or older with locally advanced oropharyngeal carcinoma. Cancer, 2018, 124, 4322-4331.	4.1	8
44	Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. , 2018, 6, 46.		135
45	Combined modality radiation therapy promotes tolerogenic myeloid cell populations and STAT3-related gene expression in head and neck cancer patients. Oncotarget, 2018, 9, 11279-11290.	1.8	19
46	Checkpoint inhibitors in lung cancer: latest developments and clinical potential. Therapeutic Advances in Medical Oncology, 2016, 8, 460-473.	3.2	30